Coya Therapeutics: enhancing Tregs to treat devastating degenerative diseases

H Berman is the Chief Executive Officer of Coya Therapeutics. On 22 December 2020, he merged Nicoya Health, Inc., which he cofounded, with Coya, to realize the vision and research of S Appel. Berman has over 18 years of entrepreneurial and industry experience working at the interplay of science and business. He gained corporate experience as a Medical Science Liaison at AbbVie where he spent 7.5 years launching Venetoclax in chronic lymphocytic leukemia and later, supporting numerous solid tumor assets. He also held leadership roles at Novartis Pharmaceuticals and Eli Lilly. Berman began his career at MD Anderson Cancer Center in the technology transfer division where he was responsible for assessing the market, patent and scientific merits of numerous oncology-based technology platforms in order to ascertain their commercial viability. He received a Bachelor’s degree in Biology from the University of Michigan and a Master’s degree and PhD in Neuroscience and Pharmacology from Weill Cornell Medical School.